Crossmark

Characteristics, risk factors and a risk prediction model of tocilizumab-induced hypofibrinogenemia: a retrospective real-world study of inpatients

Published Online: 2025-01-09

Authors

Cai, Le

Wen, Xiao

Qiu, Zihan

Fu, An

Guo, Daihong

Zhu, Man https://orcid.org/0000-0003-0627-2800
Funding

Funding for this research was provided by:

The Special research project on monitoring and evaluation of the use of key clinical drugs by the committee for drug evaluation of Chinese research hospital association (Y2023FH-YWPJ03-101)

Capital’s Funds for Health Improvement and Research (2024-2-5012)
License Information

Text and Data Mining valid from 2025-01-09

Version of Record valid from 2025-01-09
More Information

Article History

Received: 16 August 2024

Accepted: 17 December 2024

First Online: 9 January 2025

Declarations

:

: This study involving humans was approved by the Ethics Committee of Chinese PLA General Hospital with a waiver of the requirement for informed consent (S2024-247-01).

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current